Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Financial Statements and ExhibitsItem 9.01
|
Exhibit No. |
Description |
| 1.1 | Underwriting Agreement, dated July 12, 2017 |
| 5.1 | Opinion of Cooley LLP |
| 23.1 | Consent of Cooley LLP (contained in Exhibit 5.1) |
ALDER BIOPHARMACEUTICALS INC ExhibitEX-1.1 2 d424171dex11.htm EX-1.1 EX-1.1 EXHIBIT 1.1 ALDER BIOPHARMACEUTICALS,…To view the full exhibit click here
About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody.
